CY1114126T1 - Μεθοδοι θεραπειας μη-αλκοολικης στεατοηπατιτιδας (nash) χρησιμοποιωντας προϊοντα κυστεαμινης - Google Patents

Μεθοδοι θεραπειας μη-αλκοολικης στεατοηπατιτιδας (nash) χρησιμοποιωντας προϊοντα κυστεαμινης

Info

Publication number
CY1114126T1
CY1114126T1 CY20131100522T CY131100522T CY1114126T1 CY 1114126 T1 CY1114126 T1 CY 1114126T1 CY 20131100522 T CY20131100522 T CY 20131100522T CY 131100522 T CY131100522 T CY 131100522T CY 1114126 T1 CY1114126 T1 CY 1114126T1
Authority
CY
Cyprus
Prior art keywords
alcoholic
treatment
steatheepatidis
nash
methods
Prior art date
Application number
CY20131100522T
Other languages
English (en)
Inventor
Ranjan Dohil
Jerry Schneider
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40679016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1114126(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of CY1114126T1 publication Critical patent/CY1114126T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η αποκάλυψη αφορά, γενικά, στη θεραπεία διαταραχών λιπαρού ήπατος που περιλαμβάνει χορήγηση συνθέσεων που περιλαμβάνουν προϊόντα, κυστεαμίνης. Η αποκάλυψη παρέχει χορήγηση εντερικώς επικαλυμμένων ενώσεων κυστεαμίνης για να παραπέμπονται διαταραχές λιπαρού ήπατος, όπως μη-αλκοολικού λιπαρού ήπατος νόσος (ΝΑFLD) και μη-αλκοολική στεατοηπατίτιδα (ΝΑSH).
CY20131100522T 2007-11-30 2013-06-27 Μεθοδοι θεραπειας μη-αλκοολικης στεατοηπατιτιδας (nash) χρησιμοποιωντας προϊοντα κυστεαμινης CY1114126T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99151707P 2007-11-30 2007-11-30
US8539708P 2008-07-31 2008-07-31
EP08853916A EP2214480B1 (en) 2007-11-30 2008-11-28 Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products

Publications (1)

Publication Number Publication Date
CY1114126T1 true CY1114126T1 (el) 2016-07-27

Family

ID=40679016

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100522T CY1114126T1 (el) 2007-11-30 2013-06-27 Μεθοδοι θεραπειας μη-αλκοολικης στεατοηπατιτιδας (nash) χρησιμοποιωντας προϊοντα κυστεαμινης

Country Status (26)

Country Link
US (5) US7994226B2 (el)
EP (2) EP2636404B1 (el)
JP (3) JP5583022B2 (el)
KR (1) KR20100091219A (el)
CN (2) CN101932238B (el)
AR (1) AR069500A1 (el)
AU (1) AU2008329628B2 (el)
BR (1) BRPI0819690B8 (el)
CA (1) CA2706768C (el)
CL (1) CL2008003582A1 (el)
CY (1) CY1114126T1 (el)
DK (1) DK2214480T3 (el)
ES (1) ES2417179T3 (el)
HK (1) HK1141945A1 (el)
HR (1) HRP20130590T1 (el)
IL (2) IL205909B (el)
MX (2) MX360827B (el)
MY (1) MY156316A (el)
NZ (1) NZ585732A (el)
PL (1) PL2214480T3 (el)
PT (1) PT2214480E (el)
RU (1) RU2498795C2 (el)
SG (1) SG10201403200RA (el)
TW (2) TWI478710B (el)
WO (1) WO2009070781A1 (el)
ZA (1) ZA201003670B (el)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2535044T (pt) 2006-01-27 2020-03-26 Univ California Cistamina e bitartarato de cisteamina revestidas entericamente
CN101932238B (zh) 2007-11-30 2015-04-08 加利福尼亚大学董事会 使用半胱胺制品治疗非酒精性脂肪性肝炎(nash)的方法
CA2798735A1 (en) * 2010-05-19 2011-11-24 Haruki Shibata Prophylactic and/or therapeutic agent for non-alcoholic steatohepatitis
SG185754A1 (en) * 2010-06-08 2012-12-28 Mahesh Kandula Cysteamine derivatives and their use in the treatment of nash
US20140187594A1 (en) * 2010-07-28 2014-07-03 Orchid Chemicals And Pharmaceuticals Ltd Diphenyl ether compounds for the treatment of liver, lung disorders, diabetic complications and cardiovascular diseases
WO2014045293A1 (en) * 2012-09-24 2014-03-27 Krisani Bioscience (P) Ltd. Fatty acid amides with a cysteamine or an acetylated cysteamine group and uses thereof
BR112014006220A2 (pt) 2011-09-16 2017-04-11 Galectin Therapeutics Inc composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica
WO2013062544A1 (en) * 2011-10-26 2013-05-02 Seattle Children's Research Institute Cysteamine in the treatment of fibrotic disease
SG10201800159QA (en) * 2011-11-22 2018-02-27 Univ California Cysteamine and/or cystamine for treating ischemic injury
US20150086627A1 (en) * 2012-03-29 2015-03-26 Halo Therapeutics, Llc. Dosage forms of halofuginone and methods of use
BR112014030534A2 (pt) 2012-06-06 2017-06-27 Galectin Therapeutics Inc composições de galacto-ramnogalacturonato para o tratamento de doenças associadas com óxido nítrico sintase induzível elevada
US20140314841A1 (en) 2013-04-19 2014-10-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Use of Cysteamine and Derivatives Thereof to Suppress Tumor Metastases
AR096628A1 (es) * 2013-06-17 2016-01-20 Raptor Pharmaceuticals Inc Formulación en perlas de cisteamina de liberación retardada y métodos de preparación y uso de ella
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
CN106659722A (zh) * 2014-04-18 2017-05-10 株式会社Lg生命科学 用于预防或治疗脂肪肝疾病的组合物
EP3266461A4 (en) * 2015-03-03 2018-11-14 KOHJIN Life Sciences Co., Ltd. Composition for improving or preventing nonalcoholic fatty liver
ES2770113T3 (es) 2015-07-02 2020-06-30 Horizon Orphan Llc Análogos de la cisteamina resistentes a la ADO y sus usos
RU2595815C1 (ru) * 2015-07-13 2016-08-27 федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Западный государственный медицинский университет им. И.И. Мечникова" Министерства здравоохранения Российской Федерации Способ лечения больных неалкогольным стеатогепатитом на фоне метаболического синдрома
US10537528B2 (en) 2015-11-16 2020-01-21 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine compounds
US10143665B2 (en) 2015-11-17 2018-12-04 Horizon Orphan Llc Methods for storing cysteamine formulations and related methods of treatment
JP7418958B2 (ja) * 2016-03-17 2024-01-22 チオジェネシス セラピューティクス， インコーポレイテッド システアミンの制御放出のための組成物及びシステアミン感受性障害の全身治療
ITUA20161799A1 (it) * 2016-03-18 2017-09-18 Recordati Ind Chimica E Farmaceutica S P A Composizione farmaceutica a rilascio prolungato comprendente cisteamina o un suo sale
EP3634411B1 (en) * 2017-06-08 2023-09-20 N-Gene Research Laboratories Inc. Methods for treating nash and for preventing nash-induced hcc
US10632092B2 (en) 2017-08-30 2020-04-28 First Fruits Business Ministry, Llc Composition for and method to increase serum adiponectin and reduce body fat
CN111683684B (zh) * 2017-09-20 2024-07-02 硫创治疗公司 用于治疗半胱胺敏感性病症的方法
KR102177304B1 (ko) * 2018-07-23 2020-11-10 제이투에이치바이오텍 (주) 비알콜성 지방간염의 예방 또는 치료용 약학 조성물
CN111544426A (zh) * 2019-02-12 2020-08-18 复旦大学 炔丙基半胱氨酸及其在制备新靶点药物中的用途
EP3946298A4 (en) 2019-03-26 2023-01-25 The Regents of the University of California SUBSTITUTED AMINO-THIOL AND AMINODISULFIDE COMPOUNDS AND THEIR USES
JP2022542840A (ja) * 2019-07-19 2022-10-07 フィルトリシン， インコーポレイテッド がん処置および代謝介入療法および他の使用のための組成物、方法、キットならびにシステム
CN111505099B (zh) * 2020-04-21 2023-07-04 上海市普陀区中心医院 Nash的诊断标志物及其应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110441A (en) * 1974-04-29 1978-08-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Gamma-l-glutamyl cholamine phosphate
US4959306A (en) * 1986-11-28 1990-09-25 Sclavo, Inc. Labeling design for a binding assay reagent
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5639743A (en) * 1992-11-13 1997-06-17 University Of Georgia Research Foundation Compositions and methods for treating exocrine gland atrophy
JPH11302178A (ja) * 1998-02-17 1999-11-02 Otsuka Pharmaceut Factory Inc 脂肪肝予防及び治療剤
CA2236344A1 (en) * 1998-04-30 1999-10-30 Hemosol Inc. Hemoglobin-haptoglobin complexes
US20050059576A1 (en) * 1998-04-30 2005-03-17 Adamson J. Gordon Targeted delivery of antiviral compounds through hemoglobin bioconjugates
US6794414B1 (en) 1998-06-17 2004-09-21 Yeda Research And Development Co. Ltd. Method and compositions for treating diseases mediated by transglutaminase activity
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
AU2001237080A1 (en) * 2000-02-14 2001-08-20 Len Booysen Stabilizer unit
CN1144585C (zh) * 2000-12-13 2004-04-07 华扩达动物科学[I.P.2]有限公司 含有半胱胺或其盐类的促进动物快速生长的组合物及用途
US7449451B2 (en) * 2001-08-29 2008-11-11 Premier Micronutrient Corporation Use of multiple antioxidant micronutrients as systemic biological radioprotective agents against potential ionizing radiation risks
GB2379854B (en) 2001-09-19 2006-04-19 Walcom Animal Science Dairy cow feed and the use thereof
EP1461033B1 (en) * 2001-11-29 2013-02-27 Sound Pharmaceuticals Incorporated Methods and compositions for ameliorating the undesirable effects of chemotherapy
KR20040078663A (ko) * 2002-01-04 2004-09-10 사운드 파마슈티칼스 인코퍼레이티드 난청의 치료 방법
GB2386817B (en) 2002-02-20 2006-08-23 Walcom Animal Science Feed for fish and use therof
JP2004026716A (ja) 2002-06-25 2004-01-29 Ajinomoto Co Inc ＴＮＦα産生の抑制剤
US8017651B2 (en) 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
GB2398497A (en) 2003-02-19 2004-08-25 Walcom Animal Science Composition for improving immunity of animals
WO2005049002A1 (en) 2003-11-19 2005-06-02 Omega Bio-Pharma International Ltd. Materials and methods for improving alcohol metabolism and alleviating the effects of hangovers
CN101897970A (zh) 2003-12-19 2010-12-01 奥加生物药业(I.P.3)有限公司 用于治疗糖尿病的组合物和方法
US20050209441A1 (en) 2004-03-22 2005-09-22 Lile Jackson D Process for promoting proper folding of human serum albumin using a human serum albumin ligand
CA2565250C (en) * 2004-05-03 2013-11-12 Omega Bio-Pharma (I.P.3) Limited Cysteamines for treating complications of hypercholesterolemia and diabetes
AP2007004084A0 (en) 2005-01-05 2007-08-31 Fisher Cormack & Botha Taurine synthesis production and utility as a medicine
PL1879599T3 (pl) * 2005-04-20 2014-03-31 Hutchinson Fred Cancer Res Sposoby, kompozycje i wyroby do zwiększania przeżywalności komórek, tkanek, narządów i organizmów
BRPI0620255A2 (pt) * 2005-12-21 2011-11-08 Schering Corp uso de agentes redutores de colesterol e/ou antagonista/agonista inverso do receptor de h3
US20070172514A1 (en) * 2006-01-20 2007-07-26 Francis Chi Materials and methods for improving livestock productivity
PT2535044T (pt) * 2006-01-27 2020-03-26 Univ California Cistamina e bitartarato de cisteamina revestidas entericamente
WO2007121545A1 (en) * 2006-04-20 2007-11-01 Universidade Estadual De Campinas-Unicamp S-nitrosothiols containing compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions
AU2007248483A1 (en) 2006-05-03 2007-11-15 Geisinger Clinic Methods for diagnosing and predicting non-alcoholic steatohepatitis (NASH)
WO2008093764A1 (ja) 2007-02-02 2008-08-07 Kaneka Corporation 糖尿病予防または治療用組成物
CN101932238B (zh) 2007-11-30 2015-04-08 加利福尼亚大学董事会 使用半胱胺制品治疗非酒精性脂肪性肝炎(nash)的方法

Also Published As

Publication number Publication date
AU2008329628A1 (en) 2009-06-04
MY156316A (en) 2016-02-11
US20160143865A1 (en) 2016-05-26
IL205909A0 (en) 2010-11-30
US9149448B2 (en) 2015-10-06
CN104825430A (zh) 2015-08-12
CN104825430B (zh) 2018-05-04
HRP20130590T1 (en) 2013-08-31
EP2214480B1 (en) 2013-03-27
TW200927093A (en) 2009-07-01
RU2010126631A (ru) 2012-01-10
WO2009070781A1 (en) 2009-06-04
BRPI0819690B8 (pt) 2021-05-25
BRPI0819690A2 (pt) 2014-10-07
BRPI0819690B1 (pt) 2019-07-30
US9511038B2 (en) 2016-12-06
US20130183351A1 (en) 2013-07-18
CA2706768C (en) 2016-06-28
TW201513855A (zh) 2015-04-16
MX360827B (es) 2018-11-16
JP2011505375A (ja) 2011-02-24
PT2214480E (pt) 2013-07-23
DK2214480T3 (da) 2013-07-08
ZA201003670B (en) 2011-08-31
US7994226B2 (en) 2011-08-09
CA2706768A1 (en) 2009-06-04
EP2636404B1 (en) 2019-03-20
CL2008003582A1 (es) 2009-04-03
EP2214480A4 (en) 2010-09-29
AR069500A1 (es) 2010-01-27
US10307386B2 (en) 2019-06-04
EP2214480A1 (en) 2010-08-11
HK1141945A1 (en) 2010-11-26
CN101932238A (zh) 2010-12-29
IL205909B (en) 2018-05-31
ES2417179T3 (es) 2013-08-06
TWI535435B (zh) 2016-06-01
JP5583022B2 (ja) 2014-09-03
IL254586A0 (en) 2017-11-30
JP6121951B2 (ja) 2017-04-26
TWI478710B (zh) 2015-04-01
MX2010005921A (es) 2010-06-11
PL2214480T3 (pl) 2013-11-29
AU2008329628B2 (en) 2014-06-26
US8263662B2 (en) 2012-09-11
EP2636404A2 (en) 2013-09-11
RU2498795C2 (ru) 2013-11-20
EP2636404A3 (en) 2013-10-16
SG10201403200RA (en) 2014-10-30
US20120015005A1 (en) 2012-01-19
JP2017165735A (ja) 2017-09-21
US20100303870A1 (en) 2010-12-02
US20170304233A1 (en) 2017-10-26
NZ585732A (en) 2012-02-24
KR20100091219A (ko) 2010-08-18
CN101932238B (zh) 2015-04-08
JP2014237670A (ja) 2014-12-18

Similar Documents

Publication Publication Date Title
CY1114126T1 (el) Μεθοδοι θεραπειας μη-αλκοολικης στεατοηπατιτιδας (nash) χρησιμοποιωντας προϊοντα κυστεαμινης
CY1122161T1 (el) Συζευγμενα αντισωματα anti-cd38
BR112014006220A2 (pt) composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica
MY158504A (en) Fatty acid niacin conjugates and their uses
EA201100030A1 (ru) Пиразольные соединения 436
UA118332C2 (uk) Білок, що зв&#39;язує антиген cd27l
WO2009126688A8 (en) Novel compositions and methods for the treatment of immune related diseases
EA201170832A1 (ru) Пуриновые соединения
MX2010008035A (es) Composicion que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes acidas.
EA201101190A1 (ru) Фармацевтическая композиция, включающая линаглиптин и необязательно ингибитор sglt2, и ее применение
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
EA201001639A1 (ru) Композиции и способы их получения и применения
EA201300242A1 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
IL197941A0 (en) Use of anilinopyrimidine derivatives for the preparation of pharmaceutical compositions for treating non-alcoholic liver diseases
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
PH12015501582B1 (en) Compositions comprising 15-hepe and methods of using the same
CY1115725T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων
EP2217238A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES RELATED TO PROTEINURIA
DE602006011127D1 (de) Fettsäure-benzenediol-derivate sowie herstellungs- und verwendungsverfahren dafür
EP3781158A4 (en) COMPOSITIONS FOR THE TREATMENT OF NON-ALCOHOLIC FAT LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS
WO2008112840A3 (en) Novel composition and methods for the treatment of immune related diseases
AU2017221784B2 (en) Novel compositions and methods for the treatment of immune related diseases
BRPI0416357A (pt) métodos e composições para inibição de selectina
WO2009151495A3 (en) Oxazole compounds, compositions and methods of use